Plasma Rich in Growth Factors as an Adjuvant Agent in Non-Penetrating Deep Sclerectomy

• Published in: Journal of clinical medicine 2023-05, Vol.12 (10), p.3604
• Main Authors: Rodríguez-Calvo, Pedro P, Rodríguez-Uña, Ignacio, Fernández-Vega-Cueto, Andrés, Sánchez-Ávila, Ronald M, Anitua, Eduardo, Merayo-Lloves, Jesús
• Format: Article
• Language: English
• Subjects: Care and treatment; Clinical medicine; Diagnosis; Evaluation; Eye; Eye surgery; Glaucoma; Growth factors; Morphology; Open-angle glaucoma; Patient outcomes; Patients; Platelet-rich plasma therapy; Safety and security measures; Surgery; Surgical outcomes; Surgical techniques; Sutures; Variance analysis
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm12103604

The purpose of this study is to evaluate the utility and safety of plasma rich in growth factors immunosafe eye drops (is-ePRGF) in the postoperative treatment of non-penetrating deep sclerectomy (NPDS). This is a case-control study in patients with open-angle glaucoma. Group one (control) was not treated with is-ePRGF, while group two (is-ePRGF) was treated (four times a day for four months). Postoperative evaluations were performed at one day, one month, three months and six months. The main outcomes were: intraocular pressure (IOP), microcysts in blebs with AS-OCT and the number of hypotensive eye drops. Preoperatively, group one ( = 48 eyes) and group two ( = 47 eyes) were similar in age (71.5 ± 10.7 vs. 70.9 ± 10.0 years; = 0.68), IOP (20.6 ± 10.2 vs. 23.0 ± 9.0 mmHg; = 0.26) and number of hypotensive drugs (2.7 ± 0.8 vs. 2.8 ± 0.9; = 0.40). The IOP at six months dropped to 15.0 ± 8.0 mmHg (IOP reduction: -27.2%) and 10.9 ± 4.3 mmHg (IOP reduction: -52.6%) for group one and group two, respectively ( < 0.01). At six months, blebs with microcysts were 62.5% (group one) and 76.7% (group two). Postoperative complications were observed in 12 eyes (25%) for group one and in 5 eyes (11%) for group two ( = 0.06). No specific complications related to the use of is-ePRGF were identified. Topical is-ePRGF seems to reduce IOP and the rate of complications in the medium term after NPDS, so it can be considered as a possible safe adjuvant to achieve surgical success.